APA (7th ed.) Citation

MH, L., RH, Y., HJ, J., HY, C., LT, K., TY, H., . . . CH, L. (2025). Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patients. Diabetology & metabolic syndrome, 17(1), 377. https://doi.org/10.1186/s13098-025-01940-0

Chicago Style (17th ed.) Citation

MH, Lin, et al. "Immune Checkpoint Inhibitor Therapy and Risk of Type 1 Diabetes Mellitus in Metastatic Cancer Patients." Diabetology & Metabolic Syndrome 17, no. 1 (2025): 377. https://doi.org/10.1186/s13098-025-01940-0.

MLA (9th ed.) Citation

MH, Lin, et al. "Immune Checkpoint Inhibitor Therapy and Risk of Type 1 Diabetes Mellitus in Metastatic Cancer Patients." Diabetology & Metabolic Syndrome, vol. 17, no. 1, 2025, p. 377, https://doi.org/10.1186/s13098-025-01940-0.